<DOC>
	<DOCNO>NCT02323867</DOCNO>
	<brief_summary>This single arm pilot study patient use α/β T cell-depleted PSCT alternative donor source hematologic malignancy receive alternative donor ( unrelated partially match relate ) mobilize peripheral stem cell ( PSCs ) use CliniMACS system T cell depletion plus CD19+ B cell depletion determine efficacy determine engraftment GVHD , one year leukemia free survival .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Leukemias/lymphomas Acute myeloid leukemia , primary secondary Disease status : remission &lt; 10 % bone marrow blast Myelodysplasia Acute lymphoblastic leukemia Disease status : hematologic remission Chronic myelogenous leukemia Disease status : chronic phase , accelerate phase blast crisis second chronic phase . Mixed lineage biphenotypic acute leukemia Lymphoblastic lymphoma Disease status : remission Burkitt 's lymphoma/leukemia : Disease status remission 2 . Acceptable organ status clearance 3 . No active untreated infection . Patients possible fungal infection must least 2 week appropriate antifungal antibiotic asymptomatic 4 . Signed informed consent . 5 . Negative pregnancy test female childbearing potential . 1 . Patients meet disease , organ infectious criterion . 2 . No suitable donor Donor must either unrelated , mismatch one antigen/one antigen one allele relate , HLA match sibling .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Alternative Donor</keyword>
</DOC>